🎉 M&A multiples are live!
Check it out!

Bolt Biotherapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Bolt Biotherapeutics and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Bolt Biotherapeutics Overview

About Bolt Biotherapeutics

Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.


Founded

2015

HQ

United States of America
Employees

52

Website

boltbio.com

Financials

LTM Revenue $6.3M

LTM EBITDA n/a

EV

-$7.9M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Bolt Biotherapeutics Financials

Bolt Biotherapeutics has a last 12-month revenue of $6.3M and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Bolt Biotherapeutics achieved revenue of $7.7M and an EBITDA of -$66.5M.

Bolt Biotherapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Bolt Biotherapeutics valuation multiples based on analyst estimates

Bolt Biotherapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $7.9M $7.7M XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$74.3M -$66.5M XXX XXX XXX
EBITDA Margin -944% -864% XXX XXX XXX
Net Profit -$88.1M -$69.2M XXX XXX XXX
Net Margin -1119% -900% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Bolt Biotherapeutics Stock Performance

As of April 15, 2025, Bolt Biotherapeutics's stock price is $0.

Bolt Biotherapeutics has current market cap of $14.2M, and EV of -$7.9M.

See Bolt Biotherapeutics trading valuation data

Bolt Biotherapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$7.9M $14.2M XXX XXX XXX XXX $-1.58

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Bolt Biotherapeutics Valuation Multiples

As of April 15, 2025, Bolt Biotherapeutics has market cap of $14.2M and EV of -$7.9M.

Bolt Biotherapeutics's trades at -1.3x LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Bolt Biotherapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Bolt Biotherapeutics and 10K+ public comps

Bolt Biotherapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$7.9M XXX XXX XXX
EV/Revenue -1.0x XXX XXX XXX
EV/EBITDA 0.1x XXX XXX XXX
P/E -0.2x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 0.1x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Bolt Biotherapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Bolt Biotherapeutics Valuation Multiples

Bolt Biotherapeutics's NTM/LTM revenue growth is -45%

Bolt Biotherapeutics's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $1.5M for the same period.

Over next 12 months, Bolt Biotherapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Bolt Biotherapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Bolt Biotherapeutics and other 10K+ public comps

Bolt Biotherapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -2% XXX XXX XXX XXX
EBITDA Margin -864% XXX XXX XXX XXX
EBITDA Growth -11% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -909% XXX XXX XXX XXX
Revenue per Employee $0.1M XXX XXX XXX XXX
Opex per Employee $1.5M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 240% XXX XXX XXX XXX
R&D Expenses to Revenue 747% XXX XXX XXX XXX
Opex to Revenue 987% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Bolt Biotherapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Vaccines & Immunotherapies comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Bolt Biotherapeutics M&A and Investment Activity

Bolt Biotherapeutics acquired  XXX companies to date.

Last acquisition by Bolt Biotherapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Bolt Biotherapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Bolt Biotherapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Bolt Biotherapeutics

When was Bolt Biotherapeutics founded? Bolt Biotherapeutics was founded in 2015.
Where is Bolt Biotherapeutics headquartered? Bolt Biotherapeutics is headquartered in United States of America.
How many employees does Bolt Biotherapeutics have? As of today, Bolt Biotherapeutics has 52 employees.
Who is the CEO of Bolt Biotherapeutics? Bolt Biotherapeutics's CEO is Mr. William P. Quinn.
Is Bolt Biotherapeutics publicy listed? Yes, Bolt Biotherapeutics is a public company listed on NAS.
What is the stock symbol of Bolt Biotherapeutics? Bolt Biotherapeutics trades under BOLT ticker.
When did Bolt Biotherapeutics go public? Bolt Biotherapeutics went public in 2021.
Who are competitors of Bolt Biotherapeutics? Similar companies to Bolt Biotherapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Bolt Biotherapeutics? Bolt Biotherapeutics's current market cap is $14.2M
What is the current revenue of Bolt Biotherapeutics? Bolt Biotherapeutics's last 12-month revenue is $6.3M.
What is the current EV/Revenue multiple of Bolt Biotherapeutics? Current revenue multiple of Bolt Biotherapeutics is -1.3x.
What is the current revenue growth of Bolt Biotherapeutics? Bolt Biotherapeutics revenue growth between 2023 and 2024 was -2%.
Is Bolt Biotherapeutics profitable? Yes, Bolt Biotherapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.